IMAB stock slips after mid-stage data for CD73 antibody in lung cancer (NASDAQ:IMAB)
seekingalpha.com
finance
2022-05-27 14:22:22

koto_feja/E+ via Getty Images The shares of I-Mab (NASDAQ:IMAB) are trading sharply lower in the morning hours Friday after the Chinese biotech announced early Phase 2 data for its CD73 antibody uliledlimab in combination with Coherus' (CHRS) anti-PD1 therapy, toripalimab (TUOYI) in lung cancer. The updated data lined up for a presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual meeting next week were generated from three cohorts of patients with non-small cell lung cancer (NSCLC).
